Compositions and methods for cellular component transfer therapy

JP2024502697A5Inactive Publication Date: 2024-11-11JOHNS HOPKINS UNIVERSITY +5
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023527665
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-01
Filing Date
2021-11-01
Publication Date
2024-11-11
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current methods for treating inherited or acquired retinal degenerative diseases through photoreceptor cell transplantation, known as cellular component transfer therapy (CCTT), are inefficient and ineffective in generating retinal cells suitable for medical treatment.

Method used

A method for producing retinal cells in vitro, involving the dissociation of three-dimensional retinal organoids to achieve a population where at least 60% of cells express photoreceptor cell markers, using enzymes like papain or trypsin, and enhancing cell survival with B-27 or N-2 supplements, resulting in a high percentage of single photoreceptor cells suitable for transplantation.

Benefits of technology

The produced retinal cells effectively repair dysfunctional photoreceptor cells in the recipient's retina, supporting healthy cellular components and restoring visual function by importing therapeutic proteins, demonstrating efficacy across various mutation classes and types of photoreceptor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure provides a method for generating retinal cell clusters for use in cellular component transfer therapy, retinal cell clusters generated by such methods, and compositions comprising such retinal cell clusters. The present disclosure also provides the use of retinal cell clusters and compositions comprising the same for preventing and / or treating inherited retinal degenerative diseases. The present disclosure also provides a method for generating retinal cells for use in CCTT, retinal cells generated by such methods, and compositions comprising such retinal cells. The present disclosure also provides the use of retinal cells and compositions comprising the same for preventing and / or treating inherited or acquired retinal degenerative diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 108,415, filed November 1, 2020, the entire contents of which are incorporated by reference and claim priority thereto.

[0002] preface The present disclosure provides methods for generating retinal cells for use in cellular component transfer therapy, retinal cells generated by such methods, and compositions comprising such retinal cells. The present disclosure also provides uses of the retinal cells and compositions comprising same for preventing and / or treating inherited or acquired retinal degenerative diseases. [Background technology]

[0003] background Photoreceptor cell transplantation is currently under development as a treatment for blindness caused by various inherited or acquired retinal degenerative diseases. In one approach, subretinal transplantation of retinal cells results in therapeutic transfer of cytoplasm from donor to host cells. In contrast to the expectation that donor cells will remain as independently functional photoreceptors, cellular component transfer therapy ("CCTT") works by repairing dysfunctional photoreceptor cells already present in the recipient's retina. Despite recent advances in cell culture strategies that allow the production of retinal organoids as a source of donor photoreceptor cells, there is still a need for improved methods to generate retinal cells suitable for efficiently and effectively treating inherited or acquired retinal degenerative diseases by CCTT. Summary of the Invention [Means for solving the problem]

[0004] Summary of the Invention The present disclosure provides a method for generating retinal cells for use in CCTT, retinal cells generated by such a method, and compositions comprising such retinal cells. The present disclosure also provides the use of the retinal cells and compositions comprising the same for preventing and / or treating inherited or acquired retinal degenerative diseases.

[0005] In certain embodiments, the present disclosure is directed to an in vitro method for producing a retinal cell population, in which at least about 60% of the cells of the retinal cell population express a marker for photoreceptor cell identity, the method comprising: (a) generating three-dimensional retinal organoids; (b) dissociating the three-dimensional retinal organoids; and (c) selecting a retinal cell population, in which at least about 60% of the cells of the retinal cell population express a marker for photoreceptor cell identity.

[0006] In certain embodiments, the marker of photoreceptor cell identity is CRX or RCVRN.

[0007] In certain embodiments, the three-dimensional retinal organoid is dissociated by enzyme.In certain embodiments, the enzyme is papain or trypsin.In certain embodiments, the retinal cell is contacted with a composition to ensure that the cell remains in dissociated cell suspension.In certain embodiments, the composition for ensuring that the cell remains in dissociated cell suspension comprises DNAse.In certain embodiments, the retinal cell is contacted with a composition for enhancing cell survival in dissociated cell suspension.In certain embodiments, the composition for enhancing cell survival in dissociated cell suspension comprises B-27 cell culture supplement (Thermo Fisher Scientific) or N-2 cell culture supplement (Thermo Fisher Scientific).

[0008] In certain embodiments, the three-dimensional retinal organoids reach between about DD45 and DD300 before being dissociated. In certain embodiments, the three-dimensional retinal organoids reach between about DD90 and about DD140 before being dissociated.

[0009] In certain embodiments, the retinal cell population is composed of at least about 70% single cells. In certain embodiments, the retinal cell population is composed of at least about 80% single cells. In certain embodiments, the retinal cell population is composed of at least about 90% single cells.

[0010] In certain embodiments, the retinal cell population comprises about 15% to about 45% cone photoreceptor cells, in which (a) more than about 30% express CNGA3, (b) more than about 30% express CNGB3, (c) more than about 20% express ARR3, (d) at least about 3% express THRB, and / or (e) at least about 1 cell expresses S-opsin.

[0011] In certain embodiments, the retinal cell population comprises about 55% to about 85% rod photoreceptor cells, of which (a) more than about 50% express NRL, (b) more than about 40% express NR2E3, (c) more than about 20% express PDE6B, (d) more than about 30% express CNGA1, and / or (e) at least about one cell expresses RHO.

[0012] In certain embodiments, the retinal cell population comprises: (a) less than about 10% of the cells express markers of bipolar cell identity; (b) less than about 20% of the cells express markers of Müller glial cell identity; (c) less than about 10% of the cells express markers of retinal microglial cell identity; (d) less than about 5% of the cells express markers of forebrain neural progenitor cell identity; and (e) less than about 3% of the cells express markers of retinal progenitor cell identity. In certain embodiments, the markers of bipolar cell identity are one or more of ISL1, SEBOX, CAPB5, BHLHE23, GRM6, SCGN, NRN1L, GRIK1, KLHDC8A, and PROX1; the markers of Müller glial cell identity are one or more of AQP4, PRDX6, VIM, HES1, SLC1A3, GLUL, CLU, RLBP1, and LHX2; the markers of retinal microglial cell identity are one or more of PTPRC, MPEG1, and CXCR1; the markers of forebrain neural progenitor cell identity are one or more of NKX2.2, RGCC, NEUROD1, BTG2, GADD45A, and GADD45G; and the markers of retinal progenitor cell identity are one or more of HOPX, CDK4, CCND2, VSX2, and CCND1.

[0013] In certain embodiments, the retinal cell populations described herein include: (a) less than about 10% of the cells express markers of horizontal cell identity, (b) less than about 10% of the cells express markers of ganglion cell identity, (c) less than about 5% of the cells express markers of retinal amacrine cell identity, (d) less than about 5% of the cells express markers of astrocytic cell identity, (e) less than about 5% of the cells express markers of pericyte cell identity, (f) less than about 5% of the cells express markers of vascular cell identity, and / or (g) less than about 10% of the cells express markers of retinal pigment epithelial cell identity. In certain embodiments, the markers of horizontal cell identity are one or more of ONECUT2, ONECUT1 and LHX1, the markers of ganglion cell identity are one or more of POU4F1, THY1, BRN3B and SNCG, the markers of retinal amacrine cell identity are one or more of TFAP2B, ELAVL3 and ELAVL4, and the markers of retinal pigment epithelial cell identity are one or more of BEST1, TIMP3, GRAMD3 and PITPNA.

[0014] In certain embodiments, the retinal cell population comprises no more than about 1 cell that expresses CD15 or CD133, and / or less than about 30% of the cells that express A2B5 and CD38.

[0015] In certain embodiments, the stem cells are selected from human, non-human primate or rodent non-embryonic stem cells; human, non-human primate or rodent embryonic stem cells; human, non-human primate or rodent induced pluripotent stem cells; and human, non-human primate or rodent recombinant pluripotent cells.

[0016] In certain embodiments, the present disclosure is directed to a cell population of in vitro differentiated retinal cells, wherein the in vitro differentiated retinal cells are obtained by the methods described herein.

[0017] In certain embodiments, the present disclosure is directed to a composition comprising in vitro differentiated retinal cells, wherein the in vitro differentiated retinal cells are obtained by a method described herein, in certain embodiments, the composition is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0018] In certain embodiments, the present disclosure is directed to a method for preventing and / or treating inherited or acquired retinal degenerative disease in a subject, comprising administering to the subject an effective amount of one of the following: (a) a retinal cell population described herein, or (b) a retinal cell composition described herein.In certain embodiments, the inherited retinal degenerative disease is selected from retinitis pigmentosa, choroideremia, Stargardt's disease, cone-rod dystrophy, and Leber's congenital amaurosis.In certain embodiments, the acquired retinal degenerative disease is age-related macular degeneration. [Brief description of the drawings]

[0019] [Figure 1] FIG. 1 depicts an exemplary model of retinal cellular component transfer therapy.

[0020] [Diagram 2] FIG. 2 depicts the engraftment of donor photoreceptor cells harvested from genetically GFP-labeled mice and transplanted into wild-type adult mice.

[0021] [Diagram 3] FIG. 3 illustrates the predictive and established validity of CCTT in multiple mutation classes, including mitochondrial mutations.

[0022] [Figure 4]Figure 4 depicts the results of xenograft experiments to validate that physiologically and / or therapeutically relevant proteins are susceptible to CCTT. Close analogs of the proposed CCTT human donor cells were transplanted into recipient wild-type mice. After 2-4 weeks, recipient retinas were harvested and the grafts were removed. Recipient retinas were lysed and processed for bulk proteomics. Transferred cellular proteins include proteins with functions related to membrane-bound organelles, the endoplasmic reticulum, the extracellular matrix, and other cellular compartments or components.

[0023] [Diagram 5] Figure 5 depicts the results of a homologous modeling experiment in which genetically GFP-labeled photoreceptor cells from functionally competent postnatal donors were transplanted into a double knockout adult recipient mouse model of rod and cone transducin complex deficiency. RGC function was measured in situ after 4–6 weeks: light responses from RGCs in transplanted retinas. Five consecutive recordings. Top, cell response; bottom, light stimulation pattern. The holding potential is set at -70 mV, close to the reversal potential of Cl-, to record excitatory postsynaptic currents (EPSCs). RGCs were recorded at 32–35 °C in Ames buffer. Photopic full-field white light stimuli (2 s duration, 2 s intermittency) were used to evoke responses. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Detailed Description The present disclosure provides methods for generating retinal cells for use in cellular component transfer therapy, retinal cells generated by such methods, and compositions comprising such retinal cells. The present disclosure also provides uses of the retinal cells and compositions comprising same for preventing and / or treating inherited or acquired retinal degenerative diseases.

[0025] Non-limiting embodiments of the subject matter of the present disclosure have been described herein and by way of example. For purposes of clarity of disclosure, and not by way of limitation, the detailed description is divided into the following subsections: 1. Definition, 2. A method for generating retinal cells; 3. Retinal cell populations and compositions, and 4. Methods for treating inherited retinal degenerative diseases.

[0026] 1.Definition The terms used herein generally have their ordinary meaning in the art, within the context of this disclosure, and in the specific context in which each term is used. Certain terms are described below or elsewhere in this specification to provide the practitioner with additional guidance in describing the compositions and methods of the present disclosure and how to make and use them.

[0027] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by a person skilled in the art, which will depend in part on how the value is measured or determined, i.e., on the limitations of the measurement system. For example, "about" can mean within 3 or more standard deviations, as is customary in the art. Alternatively, "about" can mean within a range of up to 20%, e.g., up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, e.g., within 5-fold or within 2-fold, of a value.

[0028] As used herein, the term "cell population" or "cell population" refers to a group of at least two cells. In non-limiting examples, a cell population can include at least about 10, at least about 100, at least about 200, at least about 300, at least about 400, at least about 500, at least about 600, at least about 700, at least about 800, at least about 900, at least about 1000 cells. A population can be a pure population that includes one cell type, such as a population of photoreceptor cells or a population of undifferentiated stem cells. Alternatively, a population can include two or more cell types, e.g., a mixed cell population. In certain embodiments, the cells in a population of cells are completely dissociated from each other, e.g., the population of cells is a suspension of individual cells. In certain embodiments, a population of cells includes clusters of undissociated cells. By way of example and not by way of limitation, such a population of cells can include up to about 1%, up to about 2%, up to about 3%, up to about 4%, up to about 5%, up to about 6%, up to about 7%, up to about 8%, up to about 9%, or up to about 10% of the cells in the population that are present as undissociated clusters containing up to about 10 cells. In certain embodiments, such a population of cells can include up to about 1%, up to about 2%, up to about 3%, up to about 4%, up to about 5%, up to about 6%, up to about 7%, up to about 8%, up to about 9%, or up to about 10% of the cells in the population that are present as undissociated clusters containing up to about 25 cells.

[0029] As used herein, the term "stem cell" refers to a cell that has the capacity to divide indefinitely in culture and give rise to specialized cells.

[0030] As used herein, the terms "embryonic stem cell" and "ESC" refer to primitive (undifferentiated) cells derived from preimplantation stage embryos, which can divide without differentiation for extended periods in culture and are known to develop into cells and tissues of the three primary germ layers. Human embryonic stem cells refer to embryonic stem cells derived from human embryos. As used herein, the terms "human embryonic stem cell" or "hESC" refer to a type of pluripotent stem cell derived from early human embryos up to and including the blastocyst stage, which can divide without differentiation for extended periods in culture and are known to develop into cells and tissues of the three primary germ layers.

[0031] As used herein, the term "embryonic stem cell line" refers to a population of embryonic stem cells cultured under in vitro conditions that allow proliferation for up to a few days, months or years without differentiation.

[0032] As used herein, the term "totipotency" refers to the ability to give rise to all of the cell types of the body, as well as all of the cell types that make up extraembryonic tissues, such as the placenta.

[0033] As used herein, the term "multipotent" refers to the capacity to develop into more than one cell type of the body.

[0034] As used herein, the term "pluripotency" refers to the capacity to develop into an organism's three developmental germ layers, including endoderm, mesoderm and ectoderm.

[0035] As used herein, the term "induced pluripotent stem cell" or "iPSC" refers to a type of pluripotent stem cell formed by the introduction of certain embryonic genes, such as but not limited to the OCT4, SOX2 and KLF4 transgenes (see, e.g., Takahashi and Yamanaka Cell 126, 663-676 (2006), incorporated herein by reference), into somatic cells.

[0036] As used herein, the term "somatic cell" refers to any cell in the body other than a gamete (egg or sperm), which are sometimes referred to as an "adult" cell.

[0037] As used herein, the term "somatic (adult) stem cells" refers to relatively rare undifferentiated cells found in many organs and differentiated tissues that have a limited capacity for both self-renewal (in the laboratory) and differentiation.

[0038] As used herein, the term "proliferation" refers to an increase in cell number.

[0039] As used herein, the term "undifferentiated" refers to cells that have not yet developed into a specialized cell type.

[0040] As used herein, the term "differentiation" refers to the process by which unspecialized embryonic cells acquire the characteristics of specialized cells, such as retinal, heart, liver or muscle cells. Differentiation is usually controlled by the interaction of the cell's genes with the physical and chemical conditions outside the cell through signaling pathways involving proteins embedded in the cell surface.

[0041] As used herein, the term "directed differentiation" refers to the manipulation of stem cell culture conditions to induce differentiation into a specific (e.g., desired) cell type, such as a retinal cell. In reference to stem cells, "directed differentiation" refers to the use of small molecules, growth factor proteins and other growth conditions to promote the transition of stem cells from a pluripotent state to a more mature or specialized cell fate.

[0042] As used herein, the term "inducing differentiation" refers to changing a default cell type (gene expression profile and / or phenotype) in reference to a cell to a non-default cell type (gene expression profile and / or phenotype). Thus, "inducing differentiation in stem cells" refers to inducing stem cells (e.g., human stem cells) to divide into progeny cells that have characteristics that differ from the stem cell, such as in gene expression profile (e.g., changes in gene expression determined by genetic analysis such as microarrays) and / or phenotype (e.g., changes in the number or presence of protein markers, e.g., cell surface markers, of rod or cone photoreceptor cells, such as CRX, RCVRN, CNGA3, CNGB3, ARR3, THRB, S-opsin, NRL, NR2E3, PDE6B, CNGA1, and RHO).

[0043] As used herein, the term "cell culture" refers to the growth of cells in vitro in an artificial medium for research or medical treatment.

[0044] As used herein, the term "culture medium" refers to a liquid that contains nutrients to cover and grow and support cells in a culture vessel such as a Petri plate, multi-well plate, spinner flask, etc. Culture medium can also include growth factors that are added to produce desired changes in the cells.

[0045] As used herein, the term "contacting" a cell(s) with a compound (e.g., at least one inhibitor, activator and / or inducer) refers to providing the compound in a location that allows the cell(s) to access the compound. Contacting can be accomplished using any suitable method. For example, contacting can be accomplished by adding a concentrated form of the compound to a cell or population of cells to reach a desired concentration, e.g., in the context of cell culture. Contacting can also be accomplished by including the compound as a component of a formulated culture medium.

[0046] As used herein, the term "in vitro" refers to an artificial environment and to processes or reactions that occur within an artificial environment. In vitro environments are exemplified, but are not limited to, test tubes and cell cultures.

[0047] As used herein, the term "in vivo" refers to the natural environment (eg, an animal or a cell) and to processes or reactions that occur within a natural environment, such as embryonic development, cell differentiation, retinogenesis, etc.

[0048] As used herein, the term "expressing," with respect to a gene or protein, refers to making mRNA or protein that can be observed using assays such as microarray assays, antibody staining assays, and the like.

[0049] As used herein, the term "marker" or "cell marker" refers to a gene or protein that identifies a particular cell or cell type. Cellular markers do not have to be limited to one marker, but can refer to a "pattern" of markers, such that a specified group of markers can identify one cell or cell type from another cell or cell type.

[0050] As used herein, the terms "derived from" or "established from" or "differentiated from" when used in reference to any cell disclosed herein refer to cells obtained (e.g., isolated, purified, etc.) from the ultimate parent cell in a cell line, tissue (such as a dissociated embryo) or body fluid using any manipulation, including, but not limited to, single cell isolation, in vitro culture, treatment and / or mutagenesis, such as with proteins, chemicals, irradiation, infection with a virus, transfection with a DNA sequence such as a morphogen, selection (such as by continuous culture), etc., of any cell contained in a cultured parent cell. Derived cells can be selected from a mixed population based on response to growth factors, cytokines, selected courses of cytokine treatment, adherence, lack of adherence, sorting procedures, etc.

[0051] An "individual" or "subject" as used herein refers to a human or non-human animal, e.g., a vertebrate such as a mammal. Mammals include, but are not limited to, humans, non-human primates, farm animals, sport animals, rodents, and pets. Non-limiting examples of non-human animal subjects include rodents, such as mice, rats, hamsters, and guinea pigs; rabbits; dogs; cats; sheep; pigs; goats; cows; horses; and non-human primates, such as apes and monkeys.

[0052] As used herein, the term "disease" refers to any condition or disorder that damages or interferes with the normal function of a cell, tissue or organ.

[0053] As used herein, the term "treating" or "treatment" refers to clinical intervention in an attempt to change the disease course of the individual or cell being treated, and can be performed for prophylaxis or during the course of clinical pathology. The therapeutic effect of treatment includes, without limitation, preventing the occurrence or recurrence of disease, alleviating symptoms, reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, amelioration or alleviation of the disease state, and remission or improved prognosis. By preventing disease progression, treatment can prevent disease deterioration in affected or diagnosed subjects or subjects suspected of having the disease, but treatment can also prevent the onset of disease or disease symptoms in subjects at risk of disease or suspected of having the disease.

[0054] 2. How to Generate Retinal Cells 2.1. Three-dimensional cell culture of retinal cells The present disclosure provides an in vitro method for inducing differentiation of stem cells (e.g., human stem cells). The subject matter of the present disclosure provides an in vitro method for inducing differentiation of stem cells to produce retinal cells, e.g., rod and / or cone photoreceptor cells. In certain embodiments, the stem cells are pluripotent stem cells. In certain embodiments, the pluripotent stem cells are selected from embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and combinations thereof. In certain embodiments, the stem cells are multipotent stem cells. Non-limiting examples of stem cells that can be used according to the methods of the present disclosure include human, non-human primate or rodent non-embryonic stem cells, embryonic stem cells, induced non-embryonic pluripotent cells, and engineered pluripotent cells. In certain embodiments, the stem cells are human stem cells. Non-limiting examples of human stem cells include human pluripotent stem cells (hPSCs) (including but not limited to human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs)), human parthenogenetic stem cells, primordial germ cell-like pluripotent stem cells, epiblast stem cells, F-class pluripotent stem cells, somatic stem cells, cancer stem cells, or any other cells capable of lineage-specific differentiation. In certain embodiments, the stem cells are embryonic stem cells (ESCs). In certain embodiments, the stem cells are human embryonic stem cells (hESCs). In certain embodiments, the stem cells are induced pluripotent stem cells (iPSCs). In certain embodiments, the stem cells are human induced pluripotent stem cells (hiPSCs).

[0055] In certain embodiments, the in vitro method for inducing stem cell differentiation to produce retinal cells of the present disclosure includes the use of factors that promote rod and cone photoreceptor fate specification and survival. In certain embodiments, the in vitro method for inducing stem cell differentiation to produce retinal cells of the present disclosure includes the use of factors that suppress retinal interneuron, e.g., bipolar cells and retinal ganglion cells, fate specification and survival. In certain embodiments, the in vitro method for inducing stem cell differentiation to produce retinal cells of the present disclosure includes the use of factors that suppress retinal glia, e.g., Müller glia, fate specification and survival. In certain embodiments, the in vitro method for inducing stem cell differentiation to produce retinal cells of the present disclosure includes the use of factors that (a) promote rod and cone photoreceptor fate specification and survival, suppress retinal interneuron, e.g., bipolar cells and retinal ganglion cells, fate specification and survival, and / or (c) suppress retinal glia, e.g., Müller glia, fate specification and survival.

[0056] In certain embodiments, the present disclosure is directed to the generation of three-dimensional retinal organoids, for example, three-dimensional human retinal organoids. By way of example and not limitation, strategies for generating three-dimensional human retinal organoids can be used as described in Eldred et al., Science, 362:6411 (2018); Zhong et al., Nat Commun., 5:4047 (2014); Reichman et al., Stem Cells, 35:1176-88 (2017); Wahlin et al., Sci Rep., 7:766 (2017); Hallam et al., Stem Cells, 36:1535-51 (2018); Kaya et al., Mol. Vis., 25: 663-678 (2019); or Regent et al., Mol Vis., 26: 97-105 (2020), each of which is incorporated by reference in its entirety. In certain embodiments, human retinal organoids are differentiated to reach a specific ratio of cone subtypes (red / long, green / medium and blue / short). By way of example and not by way of limitation, culturing organoids in the presence of low concentrations of retinoic acid (RA), for example, less than about 1 μM RA, results in organoids with a high ratio of red cones. In certain exemplary embodiments, culturing organoids in high concentrations of RA, for example, greater than about 1 μM to about 20 μM RA (or knockout of CYP26a1), results in organoids with a high ratio of blue and green cones. In certain exemplary embodiments, culturing organoids in RA until day 80 results in a peripheral mixture of red, green and blue cones. In certain exemplary embodiments, culturing organoids in high concentrations of thyroid hormone (T3), for example, about 1 nM to about 1 μM T3, and high concentrations of RA, for example, about 1 μM to about 20 μM RA, results in organoids with high ratio of green cones.In certain exemplary embodiments, culturing organoids in high concentrations of T3, for example, about 1 nM to about 1 μM T3, and low concentrations of RA, for example, less than about 1 μM RA, results in organoids with high ratio of red cones.In certain exemplary embodiments, knockout of the thyroid hormone receptor in organoids results in a high ratio of blue cones.

[0057] In certain embodiments, the differentiation of stem cells into retinal organoids comprises the in vitro differentiation of stem cells into cells that express at least one retinal organoid marker.In certain embodiments, the differentiation of stem cells into retinal organoids comprises the in vitro differentiation of stem cells into cells that show at least one morphological characteristic associated with retinal organoid differentiation.In certain embodiments, the differentiation of stem cells into retinal organoids comprises the in vitro differentiation of stem cells into cells that express at least one retinal organoid marker and show at least one morphological characteristic associated with retinal organoid differentiation.Non-limiting examples of retinal organoid markers include Nrl, Rho, Arr3 and combinations thereof.Non-limiting examples of retinal organoid morphological characteristics include (a) the development of multi-layered retinal organoid anatomical morphology, including, for example, photoreceptor outer nuclear layer and newborn outer segment, and (b) retinal pigment epithelium (RPE) pigmentation development.

[0058] In certain embodiments, the stem cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 45 days to about 300 days. In certain embodiments, the stem cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 50 days to about 300 days. In certain embodiments, the stem cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 55 days to about 300 days. In certain embodiments, the stem cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 60 days to about 300 days. In certain embodiments, the stem cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 70 days to about 300 days. In certain embodiments, the stem cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 75 days to about 300 days. In certain embodiments, the stem cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 80 days to about 300 days. In certain embodiments, the stem cells are differentiated to achieve the target differentiation stage of the cells of the retinal organoid for at least about 85 days to about 300 days.In certain embodiments, the stem cells are cultured for at least about 90 days, at least about 91 days, at least about 93 days, at least about 94 days, at least about 95 days, at least about 96 days, at least about 97 days, at least about 98 days, at least about 99 days, at least about 100 days, at least about 101 days, at least about 102 days, at least about 103 days, at least about 104 days, at least about 105 days, at least about 106 days, at least about 107 days, at least about 108 days, at least about 109 days, at least about 110 days, at least about 111 days, at least about 112 days, at least about 113 days, at least about 114 days, at least about 115 days, at least about 116 days, The cells are differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 117 days, at least about 118 days, at least about 119 days, at least about 120 days, at least about 121 days, at least about 122 days, at least about 123 days, at least about 124 days, at least about 125 days, at least about 126 days, at least about 128 days, at least about 129 days, at least about 130 days, at least about 131 days, at least about 132 days, at least about 133 days, at least about 134 days, at least about 135 days, at least about 136 days, at least about 137 days, at least about 138 days, at least about 139 days, or at least about 140 days. The duration of differentiation can be described as "DD", and for example, the cells can be differentiated to achieve a target differentiation stage of cells of retinal organoids for at least about 50 days ("DD50") to about 300 days ("DD300").

[0059] 2.2. Dissociation of retinal organoids In certain embodiments, the present disclosure is directed to the generation of a population of retinal cells by dissociating the retinal organoids described above.In certain embodiments, such dissociation involves the disruption of the layered organization of cells in the organoid.In certain embodiments, such retinal organoids are dissociated by the addition of specific enzymes and / or additives that ensure that cells remain in dissociated cell suspension and not as aggregates.By way of example and not of limitation, enzymes useful in connection with dissociating retinal organoids include papain and trypsin.Compositions useful in ensuring that cells remain in dissociated cell suspension include compositions that include DNAse.Compositions useful for enhancing the survival of cells in dissociated cell suspension include compositions that include B-27 cell culture supplement (Thermo Fisher Scientific) or N-2 cell culture supplement (Thermo Fisher Scientific).

[0060] In certain embodiments, the population of retinal cells resulting from the dissociation of the retinal organoids of the present disclosure will contain at least 70% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 70%-80% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 70%-85% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 70%-90% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell populations of the present disclosure will contain between 70%-95% single cells relative to the total number of cells (including doublets, triplets and higher clusters of undissociated cells). In certain embodiments, the cell populations of the present disclosure will contain between 70%-100% single cells relative to the total number of cells (including doublets, triplets and higher clusters of undissociated cells).

[0061] In certain embodiments, the retinal cell population resulting from the dissociation of the retinal organoids of the present disclosure will contain at least 80% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 80%-85% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 80%-90% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 80%-95% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell populations of the present disclosure will contain between 80%-100% single cells relative to the total number of cells (including doublets, triplets and higher order clusters of undissociated cells).

[0062] In certain embodiments, the retinal cell population resulting from the dissociation of the retinal organoids of the present disclosure will contain at least 85% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 85%-90% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 85%-95% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 85%-100% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells).

[0063] In certain embodiments, the retinal cell population resulting from the dissociation of the retinal organoids of the present disclosure will contain at least 90% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 90%-95% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 90%-100% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher-order clusters of undissociated cells).

[0064] In certain embodiments, the retinal cell population resulting from the dissociation of the retinal organoids of the present disclosure will contain at least 95% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher clusters of undissociated cells). In certain embodiments, the cell population of the present disclosure will contain between 95% and 100% single cells relative to the total number of cells (including doublet cells, triplet cells, and higher clusters of undissociated cells).

[0065] 2.3 Selective enrichment and / or negative selection of certain cell types In certain embodiments, the present disclosure is directed to the generation of retinal cell populations that include specific cell types. By way of example and not by way of limitation, such retinal cell populations can be selectively enriched or negatively selected for specific cell types. In certain embodiments, retinal cell populations are sorted, for example, by fluorescence activated cell sorting, to selectively enrich and / or negatively select for specific cell types.

[0066] In certain embodiments, at least about 60% of the cells of the retinal cell population of the present disclosure express a marker for photoreceptor cell identity. By way of example and not by way of limitation, the marker for photoreceptor cell identity is CRX or RCVRN. In certain embodiments, at least about 65% of the cells of the retinal cell population of the present disclosure express a marker for photoreceptor cell identity. In certain embodiments, at least about 70% of the cells of the retinal cell population of the present disclosure express a marker for photoreceptor cell identity. In certain embodiments, at least about 75% of the cells of the retinal cell population of the present disclosure express a marker for photoreceptor cell identity. In certain embodiments, at least about 80% of the cells of the retinal cell population of the present disclosure express a marker for photoreceptor cell identity. In certain embodiments, at least about 85% of the cells of the retinal cell population of the present disclosure express a marker for photoreceptor cell identity. In certain embodiments, at least about 90% of the cells of the retinal cell population of the present disclosure express a marker for photoreceptor cell identity. In certain embodiments, at least about 90% of the cells of the retinal cell population of the present disclosure express a marker of photoreceptor cell identity. In certain embodiments, at least about 95% of the cells of the retinal cell population of the present disclosure express a marker of photoreceptor cell identity. In certain embodiments, up to about 100% of the cells of the retinal cell population of the present disclosure express a marker of photoreceptor cell identity.

[0067] In certain embodiments, at least about 15% to about 45% of the cells of the retinal cell population of the present disclosure express at least one marker of cone photoreceptor cell identity. By way of example and not by way of limitation, the marker of cone photoreceptor cell identity can be CNGA3, CNGB3, ARR3, THRB, or S-opsin. In certain embodiments, at least about 20% to about 45% of the cells of the retinal cell population of the present disclosure express a marker of cone photoreceptor cell identity. In certain embodiments, at least about 25% to about 45% of the cells of the retinal cell population of the present disclosure express a marker of photoreceptor cell identity. In certain embodiments, at least about 30% to about 45% of the cells of the retinal cell population of the present disclosure express a marker of cone photoreceptor cell identity. In certain embodiments, at least about 35% to about 45% of the cells of the retinal cell population of the present disclosure express a marker of cone photoreceptor cell identity. In certain embodiments, at least about 40% to about 45% of the cells in the retinal cell populations of the present disclosure express markers of cone photoreceptor cell identity.

[0068] In certain embodiments, at least about 30% of the cells of the retinal cell population expressing at least one marker of cone photoreceptor cell identity express CNGA3. In certain embodiments, at least about 30% of the cells of the retinal cell population expressing at least one marker of cone photoreceptor cell identity express CNGB3. In certain embodiments, at least about 20% of the cells of the retinal cell population expressing at least one marker of cone photoreceptor cell identity express ARR3. In certain embodiments, at least about 3% of the cells of the retinal cell population expressing at least one marker of cone photoreceptor cell identity express THRB. In certain embodiments, at least one cell of the retinal cell population expressing at least one marker of cone photoreceptor cell identity expresses S-opsin.

[0069] In certain embodiments, at least about 30% of the cells of the retinal cell population expressing at least one marker for cone photoreceptor cell identity express CNGA3, at least about 30% of the cells of the retinal cell population expressing at least one marker for cone photoreceptor cell identity express CNGB3, at least about 20% of the cells of the retinal cell population expressing at least one marker for cone photoreceptor cell identity express ARR3, at least about 3% of the cells of the retinal cell population expressing at least one marker for cone photoreceptor cell identity express THRB, and at least one cell of the retinal cell population expressing at least one marker for cone photoreceptor cell identity expresses S-opsin.

[0070] In certain embodiments, at least about 55% to about 85% of the cells of the retinal cell population of the present disclosure express at least one marker of rod photoreceptor cell identity. By way of example and not by way of limitation, the marker of rod photoreceptor cell identity can be NRL, NR2E3, PDE6B, CNGA1 or RHO. In certain embodiments, at least about 60% to about 85% of the cells of the retinal cell population of the present disclosure express a marker of rod photoreceptor cell identity. In certain embodiments, at least about 65% to about 85% of the cells of the retinal cell population of the present disclosure express a marker of rod photoreceptor cell identity. In certain embodiments, at least about 70% to about 85% of the cells of the retinal cell population of the present disclosure express a marker of rod photoreceptor cell identity. In certain embodiments, at least about 75% to about 85% of the cells of the retinal cell population of the present disclosure express a marker of rod photoreceptor cell identity. In certain embodiments, at least about 80% to about 85% of the cells in the retinal cell populations of the present disclosure express markers of rod photoreceptor cell identity.

[0071] In certain embodiments, at least about 50% of the cells of the retinal cell population expressing at least one marker of rod photoreceptor cell identity express NRL. In certain embodiments, at least about 40% of the cells of the retinal cell population expressing at least one marker of rod photoreceptor cell identity express NR2E3. In certain embodiments, at least about 20% of the cells of the retinal cell population expressing at least one marker of rod photoreceptor cell identity express PDE6B. In certain embodiments, at least about 30% of the cells of the retinal cell population expressing at least one marker of rod photoreceptor cell identity express CNGA1. In certain embodiments, at least one cell of the retinal cell cluster expressing at least one marker of rod photoreceptor cell identity expresses RHO.

[0072] In certain embodiments, at least about 50% of the cells of the retinal cell population that express at least one marker for rod photoreceptor cell identity express NRL, at least about 40% of the cells of the retinal cell population that express at least one marker for rod photoreceptor cell identity express NR2E3, at least about 20% of the cells of the retinal cell population that express at least one marker for rod photoreceptor cell identity express PDE6B, at least about 30% of the cells of the retinal cell population that express at least one marker for rod photoreceptor cell identity express CNGA1, and at least one cell of the retinal cell population that expresses at least one marker for rod photoreceptor cell identity expresses RHO.

[0073] In certain embodiments, cells of the retinal cell populations of the present disclosure are selected to include no more than about 40% of cells expressing markers of non-photoreceptor cell identity, such as, by way of example and not limitation, markers of non-photoreceptor cell identity associated with bipolar cells, Muller glia cells, retinal microglia, forebrain neural progenitor cells, retinal progenitor cells, horizontal cells, ganglion cells, retinal amacrine cells, and retinal pigment epithelial cells.

[0074] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 10% bipolar cells. In certain embodiments, the markers associated with bipolar cell identity are one or more of ISL1, SEBOX, CAPB5, BHLHE23, GRM6, SCGN, NRN1L, GRIK1, KLHDC8A and PROX.

[0075] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 20% Müller glial cells. In certain embodiments, the markers associated with Müller glial cell identity are one or more of AQP4, PRDX6, VIM, HES1, SLC1A3, GLUL, CLU, RLBP1 and LHX2.

[0076] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 10% retinal microglial cells. In certain embodiments, the marker associated with retinal microglial cell identity is one or more of PTPRC, MPEG1 and CXCR1.

[0077] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to comprise less than about 5% forebrain neural progenitor cells.In certain embodiments, the markers associated with forebrain neural progenitor cell identity are one or more of NKX2.2, RGCC, NEUROD1, BTG2, GADD45A and GADD45G.

[0078] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 3% retinal progenitor cells.In certain embodiments, the markers associated with retinal progenitor cell identity are one or more of HOPX, CDK4, CCND2, VSX2 and CCND1.

[0079] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 10% horizontal cells. In certain embodiments, the marker associated with horizontal cell identity is one or more of ONECUT2, ONECUT1 and LHX1.

[0080] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 10% retinal ganglion cells. In certain embodiments, the marker associated with retinal ganglion cell identity is one or more of POU4F1, THY1, BRN3B and SNCG.

[0081] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 5% retinal amacrine cells. In certain embodiments, the marker associated with retinal amacrine cell identity is one or more of TFAP2B, ELAVL3 and ELAVL4.

[0082] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to contain less than about 10% retinal pigment epithelial cells. In certain embodiments, the markers associated with retinal pigment epithelial cell identity are one or more of BEST1, TIMP3, GRAMD3 and PITPNA.

[0083] In certain embodiments, the cells of the retinal cell population of the present disclosure are selected such that less than 30% of the cells express a marker associated with inflammatory cell identity. By way of example and not by way of limitation, markers of inflammatory cell identity are CD15, CD133, A2B5 and CD38. In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to include less than about 30% of cells expressing A2B5 and / or CD38. In certain embodiments, the cells of the retinal cell population of the present disclosure are selected to include no more than one cell expressing CD15 or CD133.

[0084] 3. Retinal cell populations & composition The present disclosure provides a cell population of in vitro differentiated retinal cells, wherein at least about 50% (e.g., at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or at least about 99%) of the differentiated cells express at least one marker of photoreceptor cell identity.

[0085] In certain embodiments, the present disclosure provides a cell population of in vitro differentiated retinal cells, wherein at least less than about 40% (e.g., less than about 35%, less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, less than about 1%, less than about 0.5%, or less than about 0.1%) of the differentiated cells express at least one marker of non-photoreceptor cell identity.

[0086] In certain embodiments, the population of in vitro differentiated retinal cells is about 1×10 4 ~Approx. 1×10 10 , about 1×10 4 ~Approx. 1×10 5 , about 1×10 5 ~Approx. 1×10 9 , about 1×10 5 ~Approx. 1×106 , about 1×10 5 ~Approx. 1×10 7 , about 1×10 6 ~Approx. 1×10 7 , about 1×10 6 ~Approx. 1×10 8 , about 1×10 7 ~Approx. 1×10 8 , about 1×10 8 ~Approx. 1×10 9 , about 1×10 8 ~Approx. 1×10 10 or about 1 x 10 9 ~Approx. 1×10 10 Contains in vitro differentiated photoreceptor cells.

[0087] The present disclosure also provides a composition comprising such a population of in vitro differentiated retinal cells. In certain embodiments, the population of in vitro differentiated retinal cells is obtained by the differentiation method described herein. In certain embodiments, the composition is frozen. In certain embodiments, the composition further comprises at least one cryoprotectant, including but not limited to dimethyl sulfoxide (DMSO), glycerol, polyethylene glycol, sucrose, trehalose, dextrose, or a combination thereof.

[0088] In certain embodiments, the composition is a pharmaceutical composition that includes a pharma- ceutical acceptable carrier.The composition can be used to prevent and / or treat hereditary or acquired retinal degeneration disease, such as retinitis pigmentosa, choroideremia, Stargardt's disease, cone-rod dystrophy, Leber's congenital amaurosis, and age-related macular degeneration, including but not limited to "dry" age-related macular degeneration and "wet" age-related macular degeneration.

[0089] 4. Methods for Treating Inherited Retinal Degenerative Diseases The cell populations and compositions disclosed herein can be used to prevent and / or treat inherited and / or acquired retinal degenerative diseases. By way of example and not by way of limitation, the cell populations and compositions disclosed herein can be used for CCTT, which is understood to act, without being bound by theory, by repairing dysfunctional photoreceptor cells present in the recipient's retina. Again, without being bound by theory, it is understood that the cell populations and compositions disclosed herein exert their therapeutic effect, at least in part, by transferring healthy cellular components, e.g., organelles including mitochondria, along with other nuclear, cell membrane-bound and / or cytoplasmic components, e.g., therapeutic proteins. Thus, the subject matter of the present disclosure provides a method of preventing and / or treating inherited and / or acquired retinal degenerative diseases. In certain embodiments, the method comprises administering the stem cell-derived retinal cells of the present disclosure or a composition comprising the same to a subject suffering from an inherited or acquired retinal degenerative disease. In certain embodiments, the composition is a pharmaceutical composition further comprising a pharma-ceutically acceptable carrier.

[0090] CCTT is effective in multiple mutation classes. For example, CCT is effective in X-linked mutations, autosomal dominant (AD) mutations, autosomal recessive (AR) mutations and non-mendelian, such as mitochondrial mutations. In addition, for AD mutations, CCTT is effective in haploinsufficiency or dominant negative mutations (such as dominant negative interference mutations and dominant negative toxic mutations). CCTT has also been shown to be effective in the transfer of multiple types of cellular components, such as membrane-bound proteins, nuclear localized proteins, and cytoplasmic proteins. CCTT is also effective in the transfer of cellular components into both types of photoreceptor cells, i.e., rods and cones.

[0091] Non-limiting examples of inherited retinal degenerative diseases include retinitis pigmentosa, choroideremia, Stargardt's disease, cone-rod dystrophy, and Leber's congenital amaurosis. Non-limiting examples of acquired retinal degenerative diseases include age-related macular degeneration, including but not limited to "dry" age-related macular degeneration and "wet" age-related macular degeneration.

[0092] The population or composition of retinal cells described herein can be administered in any physiologically acceptable vehicle. The cells or compositions of the present disclosure can be administered by localized injection or by subretinal transplantation. In certain embodiments, the population or composition of cells will be resuspended in medium and transplanted into the subretinal space using a device that preserves its biological activity and ensures on-target placement. In certain embodiments, the device will be composed of a biocompatible material. In certain embodiments, the device will include, for example, low friction passage, which will achieve transplantation with limited shear stress on the cells. An exemplary device for subretinal transplantation is described in International Patent Application No. PCT / US2019 / 045074 (published as WO2020028892), which is incorporated herein by reference in its entirety.

[0093] The cells or compositions can be conveniently provided as a sterile liquid preparation, such as an isotonic aqueous solution, suspension, emulsion, dispersion or viscous composition, which can be buffered to a selected pH. Liquid preparations are usually easier to prepare than gels, other viscous compositions and solid compositions. Moreover, liquid compositions are somewhat more convenient to administer, especially by injection. Viscous compositions, on the other hand, can be formulated within a suitable viscosity range to provide longer contact periods with specific tissues. Liquid or viscous compositions can include carriers that can be solvents or dispersion media, including, for example, water, saline, phosphate buffered saline, polyols (e.g., glycerol, propylene glycol, liquid polyethylene glycol, etc.) and suitable mixtures thereof. Sterile injectable solutions can be prepared by incorporating the subject compositions of the present disclosure, such as compositions comprising stem cell-derived retinal cells of the present disclosure, in the required amount of a suitable solvent, with various amounts of other ingredients as required. Such compositions can be mixed with suitable carriers, diluents or excipients, such as sterile water, saline, glucose, dextrose, and the like. The compositions can also be lyophilized. Depending on the desired route of administration and preparation, the compositions can contain auxiliary substances, such as wetting agents, dispersing or emulsifying agents (e.g., methylcellulose), pH buffering agents, gelling or consistency enhancing additives, preservatives, flavoring agents, coloring agents, and the like. Suitable preparations can be prepared without undue experimentation by consulting standard texts, such as "REMINGTON'S PHARMACEUTICAL SCIENCE", 17th edition, 1985, which is incorporated herein by reference.

[0094] Various additives that enhance the stability and sterility of the composition can be added, including antimicrobial preservatives, antioxidants, chelating agents and buffers. Prevention of microbial action can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. Prolonged absorption of injectable pharmaceutical forms can be brought about by the use of agents that delay absorption, such as aluminum monostearate and gelatin.

[0095] The viscosity of the composition can be maintained at a selected level, if desired, by using a pharma- ceutically acceptable thickening agent. Methylcellulose can be used because it is readily and economically available and easy to handle. Other suitable thickening agents include, for example, hyaluronic acid, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, carbomer, and others. The concentration of the thickening agent can depend on the agent selected. The important point is to use an amount that achieves the selected viscosity. The selection of suitable carriers and other additives will depend on the exact route of administration and the nature of the particular dosage form, for example, the liquid dosage form (e.g., whether the composition is to be formulated into a solution, suspension, gel, or another liquid form, such as a time release form or a liquid fill form).

[0096] Those skilled in the art will recognize that the non-cell-derived components of the composition should generally, but not exclusively, be selected to be chemically inert and thus not affect the viability or efficacy of the retinal cells of the present disclosure. This should pose no problem to those skilled in the principles of chemistry and medicine, or the problem can be readily avoided from the present disclosure and documents cited herein by reference to standard texts or by simple experimentation (without undue experimentation).

[0097] In certain embodiments, the composition comprises an effective amount of retinal cells. As used herein, the term "effective amount" or "therapeutically effective amount" refers to an amount sufficient to affect beneficial or desired clinical results upon treatment. An effective amount can be administered to a subject in at least one dose. From a treatment perspective, an effective amount is an amount sufficient to alleviate, improve, stabilize, reverse, or slow the progression of an inherited retinal degenerative disease, or otherwise reduce the pathological consequences of an inherited retinal degenerative disease. An effective amount is generally determined by a physician on a case-by-case basis and is within the skill of a person of ordinary skill in the art. In determining the appropriate dosage to reach an effective amount, several factors are typically taken into consideration. Such factors include the age, sex, and weight of the subject, the condition being treated, the severity of the condition, and the form and effective concentration of the cells administered.

[0098] In certain embodiments, the effective amount of cells is sufficient to improve the retinal function of the subject suffering from hereditary retinal degenerative disease.In certain embodiments, the effective amount of cells is sufficient to improve the retinal function of the subject suffering from hereditary retinal degenerative disease or acquired retinal degenerative disease, for example, the improved function can be about 1%, about 5%, about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 98%, about 99% or about 100% of the retinal function of the individual who does not suffer from hereditary retinal degenerative disease or acquired retinal degenerative disease.

[0099] The amount of cells to be administered will vary for each subject being treated. In one particular embodiment, about 1×10 4 ~Approx. 1×10 10 , about 1×10 4 ~Approx. 1×10 5 , about 1×10 5 ~Approx. 1×10 9 , about 1×10 5 ~Approx. 1×10 6 , about 1×10 5 ~Approx. 1×10 7 , about 1×10 6 ~Approx. 1×10 7 , about 1×10 6~Approx. 1×10 8 , about 1×10 7 ~Approx. 1×10 8 , about 1×10 8 ~Approx. 1×10 9 , about 1×10 8 ~Approx. 1×10 10 or about 1 x 10 9 ~Approx. 1×10 10 In one particular embodiment, about 1×10 cells are administered to a subject. 5 ~Approx. 1×10 7 In one particular embodiment, about 1×10 cells are administered to a subject suffering from an inherited or acquired retinal degenerative disease. 6 ~Approx. 1×10 7 In one particular embodiment, about 1×10 cells are administered to a subject suffering from an inherited or acquired retinal degenerative disease. 6 ~Approx. 4×10 6 The cells are administered to the subject suffering from inherited retinal degenerative disease or acquired retinal degenerative disease.The exact determination of what is considered to be effective dose can be based on each subject's individual factors, including its size, age, sex, weight and condition of a particular subject.Dosage amount can be easily ascertained by those skilled in the art from this disclosure and knowledge in the art. EXAMPLES

[0100] 1. Cell repair efficacy exceeds the predicted threshold for vision restoration To estimate CCTT efficiency and validate the occurrence of CCTT among photoreceptor cells of the same species (i.e., homology modeling), postnatal day 3 GFP-producing donor photoreceptor cells were collected from genetically GFP-labeled donor mice and transplanted into wild-type adult mouse recipients. Histology was obtained 2-3 weeks after transplantation to count the number of recipient cells that underwent the process of CCTT and were labeled with GFP. The number of recipient cells was counted per section and per region of interest (ROI) to capture the inter-ROI variability in efficiency. Mouse cells were used to avoid the vulnerability of donor human cells to severe immune rejection that would compromise the goal of this experiment.

[0101] Homology modeling of cellular component transfer shows an average efficacy across all ROIs between 6.0-7.0% and a peak efficacy of approximately 30% (percentage of recipient photoreceptor cells repaired using this treatment method) in a given ROI. We predict that a repair efficiency level of 5% of recipient photoreceptor cells is the threshold for functional vision improvement.

[0102] 2. CCTT shows mutation-independent and mutation class-independent functional efficacy in both classes of recipient photoreceptor cells A series of experiments were carried out to verify the ubiquity of CCTT treatment effect. As described in Example 1, homology modeling can be used to estimate the magnitude of functional effect after CCTT between photoreceptor cells of the same species. For example, CCTT efficacy in multiple mutation classes, such as autosomal dominant (AD) vs. autosomal recessive (AR), was verified using homology modeling. Similarly, CCTT occurrence in multiple specific mutations, i.e., PRPH2 mutation vs. GNAT1 mutation vs. GNAT2 mutation, was also verified using homology modeling. CCTT efficacy in the import of multiple cellular components, such as membrane-bound protein (PRPH2) vs. cytoplasmic protein (GNAT1), was also verified using homology modeling. Finally, CCTT efficacy in both types of photoreceptor cells, i.e., both rods and cones, was verified using homology modeling. Figure 3 illustrates the predicted efficacy of CCTT in multiple mutation classes, including mitochondrial mutations, based on the results described herein.

[0103] Postnatal day 3 GFP-producing donor photoreceptor cells were harvested from genetically GFP-labeled mice and transplanted into wild-type adult mouse recipients. Functional assays were obtained 1-3 weeks after transplantation by full-field electroretinography (FF-ERG), optokinetic nystagmus (OKN) and visually guided behavior. Separate FF-ERG tests were used to probe rod vs. cone function improvement. When possible, rigor was promoted by testing the same mice at 1 week and then 1-2 weeks later to verify reproducibility. Again, donor human cells were not used in these experiments due to their vulnerability to severe immune rejection as described in Example 1.

[0104] Functional testing in a mouse model of monogenic autosomal dominant IRD showed that the majority of treated mice (>80%) recovered vision, with mean visual function improving to nearly 40% of wild-type visual acuity levels, with some reaching >85% of wild-type visual acuity levels. Functional testing in two mouse models of monogenic autosomal recessive IRD showed that the majority of treated mice (>80%) recovered vision, with mean visual function improving to nearly 50% of wild-type visual acuity levels, with some reaching >95% of wild-type visual acuity levels. Evidence of functional restoration occurs in both recipient rod and cone photoreceptor cells. In some mutations or classes of mutations, functional restoration may favor one class over the other. Furthermore, immunohistology and transcriptomics identified evidence supporting the transfer of distinct cellular components, including cytoplasmic proteins (e.g., GFP and GNAT1), RNA, albeit at low levels, and membrane-bound molecules (e.g., PRPH2) in the cells.

[0105] 3. Unbiased proteomic analysis using a cross-species approach provides evidence supporting inter-photoreceptor transfer of physiological proteins To verify that physiologically and / or therapeutically relevant proteins, e.g., mammalian proteins, rather than simply (non-mammalian) labeled proteins such as GFP, are suitable for cell-to-cell transfer by a mechanism consistent with CCTT, a xenografting approach was used. Close analogs of the CCTT human donor cells described herein were transplanted into recipient wild-type mice. After 2-4 weeks, the recipient retinas were excised and the grafts were removed. The recipient retinas were lysed and processed by bulk proteomics. As illustrated in Figure 4, this approach allows for the detection and quantification of cellular components, e.g., proteins, of one species (human) that have been transferred into cells of another species (mouse). The transferred cellular proteins include proteins with functions related to membrane-bound organelles, the endoplasmic reticulum, the extracellular matrix, and other cellular compartments or components.

[0106] 4. Whole-cell patch clamp recordings from transplanted retinas suggest that repaired cone cells respond to light stimulation. Using homology modeling, we verified that downstream visual circuits are indeed reactivated after repair of diseased recipient photoreceptor cells by a mechanism consistent with CCTT. Specifically, we measured retinal ganglion cell (RGC) function after cone repair by CCTT. RGC activity points to visual circuit reactivation, since RGCs are tertiary downstream neurons from any repaired cones. Genetically GFP-labeled photoreceptor cells from functionally competent postnatal donors were transplanted into rod transducin- and cone transducin-deficient adult recipient mice. RGC function was measured in situ after 4–6 weeks as illustrated in Figure 5: light responses from RGCs in transplanted retinas. Five consecutive recordings. Top, cell responses; bottom, light stimulation patterns. The holding potential is set at -70 mV, close to the reversal potential of Cl-, to record excitatory postsynaptic currents (EPSCs). RGCs were recorded at 32–35 °C in Ames buffer. Photopic full-field white light stimuli (2 s duration, 2 s intermittency) were used to elicit responses. The data depicted in Figure 5 indicate that CCTT-repaired photoreceptor cells respond to light stimuli and that visually evoked signals from these repaired cone cells are transmitted along recipient visual circuits, thus re-establishing visual function in previously inactive circuits.

[0107] Although the subject matter of the present disclosure and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the present disclosure. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the processes, machines, manufactures and compositions, means, methods and steps described herein. As one skilled in the art will readily recognize from the disclosure of the subject matter of the present disclosure, any currently existing or later developed process, machine, manufacture, composition, means, method or step that performs substantially the same function or achieves substantially the same result as the corresponding embodiment described herein can be utilized in accordance with the subject matter of the present disclosure. Accordingly, it is intended that the appended claims include within their scope such processes, machines, manufactures, compositions, means, methods or steps.

[0108] Various patents, patent applications, publications, product descriptions, protocols, and sequence accession numbers are cited throughout this application, the disclosures of which are incorporated by reference in their entireties for all purposes.

Claims

1. An in vitro method for producing a retinal cell population, wherein at least about 60% of the cells of said retinal cell population express a marker of photoreceptor cell identity, comprising: a. generating three-dimensional retinal organoids; b. Dissociating the three-dimensional retinal organoids; c. selecting a retinal cell population, wherein at least about 60% of the cells of said retinal cells express a marker of photoreceptor cell identity; A method comprising:

2. The method of claim 1 , wherein the marker of photoreceptor cell identity is CRX or RCVRN.

3. The method of claim 1 or 2, wherein the three-dimensional retinal organoid is enzymatically dissociated.

4. The method of claim 3, wherein the enzyme is papain and / or trypsin.

5. The method of claim 3, wherein the retinal cells are contacted with a composition to ensure that the cells remain in a dissociated cell suspension.

6. The method of claim 5 , wherein the composition is an enzyme.

7. The method of claim 6 , wherein the enzyme is a DNAse.

8. The method according to any one of claims 1 to 7, wherein the three-dimensional retinal organoids reach between about DD45 and DD300 before being dissociated.

9. 9. The method of claim 8, wherein the three-dimensional retinal organoid reaches about DD90 to about DD140 before being dissociated.

10. The method of any one of claims 1 to 9, wherein the retinal cell population consists of at least about 70% single cells.

11. The method of claim 10, wherein the retinal cell population consists of at least about 80% single cells.

12. The method of claim 10, wherein the retinal cell population consists of at least about 90% single cells.

13. 13. The method of any one of claims 1 to 12, wherein the retinal cell population comprises about 15% to about 45% cone photoreceptor cells.

14. Among the cone photoreceptor cells, a. greater than about 30% express CNGA3; b. greater than about 30% express CNGB3; c. greater than about 20% express ARR3; d. at least about 3% express THRB; and / or e. at least about one cell expresses S-opsin; The method of claim 13.

15. 15. The method of any one of claims 1 to 14, wherein the retinal cell population comprises about 55% to about 85% rod photoreceptor cells.

16. Among the rod photoreceptor cells, a. greater than about 50% express NRL; b. greater than about 40% express NR2E3; c. greater than about 20% express PDE6B; d. greater than about 30% express CNGA1; and / or e. at least about one cell expresses RHO; The method according to any one of claims 1 to 15.

17. The retinal cell population comprises: a. less than about 10% of the cells express markers of bipolar cell identity; b. less than about 20% of the cells express markers of Müller glial cell identity; c. less than about 10% of the cells express a marker of retinal microglial cell identity; d. Less than about 5% of the cells express markers of forebrain neural progenitor identity; e) The method of any one of claims 1-16, wherein less than about 3% of the cells express markers of retinal progenitor cell identity.

18. a. the marker of bipolar cell identity is one or more of ISL1, SEBOX, CAPB5, BHLHE23, GRM6, SCGN, NRN1L, GRIK1, KLHDC8A and PROX1; b. The markers of Müller glial cell identity are one or more of AQP4, PRDX6, VIM, HES1, SLC1A3, GLUL, CLU, RLBP1 and LHX2; c. The marker of retinal microglial cell identity is one or more of PTPRC, MPEG1 and CXCR1; d. the markers of forebrain neural progenitor identity are one or more of NKX2.2, RGCC, NEUROD1, BTG2, GADD45A and GADD45G; and / or e. The marker of retinal progenitor cell identity is one or more of HOPX, CDK4, CCND2, VSX2 and CCND1; 20. The method of claim 17.

19. The retinal cell population comprises: a. less than about 10% of the cells express markers of horizontal cell identity; b. less than about 10% of the cells express markers of ganglion cell identity, c. less than about 5% of the cells express markers of retinal amacrine cell identity, d. less than about 5% of the cells express markers of astrocyte cell identity; e. less than about 5% of the cells express markers of pericyte cell identity; f. less than about 5% of the cells express a marker of vascular cell identity, and / or g. Less than about 10% of the cells express a marker of retinal pigment epithelial cell identity; 19. The method according to any one of claims 1 to 18.

20. a. the marker of horizontal cell identity is one or more of ONECUT2, ONECUT1 and LHX1; b. the marker of ganglion cell identity is one or more of POU4F1, THY1, BRN3B and SNCG; c. The markers of retinal amacrine cell identity are one or more of TFAP2B, ELAVL3 and ELAVL4; d. The markers of retinal pigment epithelial cell identity are one or more of BEST1, TIMP3, GRAMD3 and PITPNA; 20. The method of claim 19.

21. The retinal cell population, a. about one or less cells expressing CD15 or CD133, and / or b. Less than about 30% of cells express A2B5 and CD38 The method according to any one of claims 1 to 18, comprising:

22. The method of any one of claims 1 to 21, wherein the stem cells are selected from human, non-human primate or rodent non-embryonic stem cells; human, non-human primate or rodent embryonic stem cells; human, non-human primate or rodent induced pluripotent stem cells; and human, non-human primate or rodent recombinant pluripotent cells.

23. The method according to any one of claims 1 to 22, wherein the stem cells are human stem cells.

24. The method according to any one of claims 1 to 23, wherein the stem cells are pluripotent or multipotent stem cells.

25. The method according to any one of claims 1 to 24, wherein the stem cells are pluripotent stem cells.

26. The method according to any one of claims 1 to 25, wherein the pluripotent stem cells are selected from embryonic stem cells, induced pluripotent stem cells, and combinations thereof.

27. A cell population of in vitro differentiated retinal cells, wherein said in vitro differentiated retinal cells are obtained by the method of any one of claims 1 to 26.

28. A composition comprising the cell population of claim 27.

29. 30. The composition of claim 28, which is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

30. 30. The composition of any one of claims 28 or 29 for use in the prevention and / or treatment of an inherited or acquired retinal degenerative disease in a subject.

31. 31. The composition for use in the prevention and / or treatment of an inherited retinal degenerative disease in a subject according to claim 30, wherein the inherited retinal degenerative disease is retinitis pigmentosa, choroideremia, Stargardt's disease, cone-rod dystrophy or Leber's congenital amaurosis.

32. 31. The composition for use in the prevention and / or treatment of an acquired retinal degenerative disease in a subject according to claim 30, wherein the acquired retinal degenerative disease is age-related macular degeneration.